§ 21. Mr. Robathan
To ask the Secretary of State for Health if he will make a statement on the current situation regarding the prescription of Infliximab. 
§ Ms Stuart
Infliximab was licensed last year for limited categories of Crohn's disease where conventional treatment has proved ineffective. The decision to prescribe infliximab is based on clinical opinion, taking into account some concerns about the long-term safety and efficacy of this drug. Healthcare commissioners will need to consider its clinical and cost effectiveness before making any decisions about funding.